A U.S. court has rejected four claims of patent infringement from Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA). The asserted claims involved the ‘250, ‘413, ‘776 and ‘302 patents for COPAXONE. The patent was about five of six Abbreviated New Drug Application (ANDA) filers.
The rejection could be such a blow to the Israel-based drugmaker given that it comes just four months after the invalidation of three patents on its drug Copaxone by the U.S. patent officials. The invalidation was occasioned by challenges posed by Mylan NV, which was somewhat was in competition with Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) with its generic version of the drug.
Teva To Appeal Court’s Decision
In a ruling, the U.S. District Court Of Delaware said that Teva’s claims were invalid. The leading global pharmaceutical company is not taking this kindly and will appeal.
Teva President and CEO, Erez Vigodman says, “We intend to move forward with an immediate appeal. We will continue to vigorously protect our COPAXONE® franchise against further challenges and through the duration of this process.”
The patents have a 2030 expiry date. They cover a 40-milligram injection of Copaxone and must be administered three times a week. At the same time while generics may also be sold it must be after a drug’s patents expire.
Let’s Explore The Scenes Behind Teva Pharmaceuticals
The company is the world’s largest generic medicines producer. It controls more than 1,800 molecules in the production of a wide range of generic products. The company, which is headquartered in Israel, delivers healthcare solutions to millions of patients.
It also treats disorders of the central nervous system. It also incorporates specialty capabilities in its global research and development division all in an effort to create new ways of addressing unmet patient needs. Meanwhile, Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA)’s stock closed at $34.52 yesterday, and is down over 7% in the premarket.
Note: This article is written by Adam Russell and originally published at Market Exclusive.